Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 6/20 | 0.46 |
| ▸ | LAP3 | P28838 | 4/20 | 0.46 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.42 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11208375 | 0.84 | LAP3 (0.52) | ANPEPLAP3ERAP1ALDH1A1TDP1 | |
| SCHEMBL14818504 | 0.78 | LAP3 (0.58) | ANPEPLAP3ERAP1ALDH1A1TDP1 | |
| SCHEMBL14818496 | 0.78 | LAP3 (0.58) | ANPEPLAP3ERAP1ALDH1A1TDP1 | |
| SCHEMBL14818494 | 0.78 | LAP3 (0.58) | ANPEPLAP3ERAP1ALDH1A1TDP1 | |
| SCHEMBL14818495 | 0.78 | LAP3 (0.58) | ANPEPLAP3ERAP1ALDH1A1TDP1 | |
| SCHEMBL14818503 | 0.78 | LAP3 (0.58) | ANPEPLAP3ERAP1ALDH1A1TDP1 | |
| SCHEMBL366378 | 0.78 | — | — | |
| SCHEMBL7512767 | 0.77 | ANPEP (0.50) | ANPEPLAP3ERAP1ALDH1A1TDP1 | |
| SCHEMBL14818491 | 0.77 | LAP3 (0.54) | ANPEPLAP3ERAP1GABBR2GABBR1 | |
| Phosphoric Acid SCHEMBL9844139 | 0.74 | ANPEP (0.41) | ANPEPLAP3ERAP1ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108713044-B | Polycarbonate resin composition and molded article thereof | 出光兴产株式会社 | 2021-08-17 | — | — | CN | disclosed |
| CN-108713044-A | Polycarbonate resin composition and molded article thereof | 出光兴产株式会社 | 2018-10-26 | — | — | CN | disclosed |
| US-8536362-B2 | β-hydroxy-γ-aminophosphonates and methods for the preparation and use thereof | NUCITEC S.A. DE C.V. (MX) | 2013-09-17 | — | — | US | disclosed |
| US-20130079308-A1 | Beta-Hydroxy-Gamma-Aminophosphonates and Methods for the Preparation and Use Thereof | NUCITEC S.A. DE C.V. (MX) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079308-A1 | Beta-Hydroxy-Gamma-Aminophosphonates and Methods for the Preparation and Use Thereof | CPT1A, ACAT1, ABAT | ANPEP 322/4885LAP3 636/4885ERAP1 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.